"uuid:ID","rationale","instanceType","id","versionIdentifier"
"b9a8798c-b602-4062-9ef1-85364a852b38","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","StudyVersion_1","2"
